H-ras localizes to cell nuclei and varies with the cell cycle

Genes and Cancer

Volumn 2, Issue 2, 2011, Pages 166-172

  Contente, Sara ^a   Yeh, Tze Jou Annie ^a   Friedman, Robert M ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Cell cycle; Cyclin D1; Farnesyltransferase inhibitor; Nuclear localization; Ras

Indexed keywords

CYCLIN D1; H RAS PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; CELL NUCLEUS; CELL STRAIN 3T3; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; FIBROBLAST; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

EID: 79960042579     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911405042     Document Type: Article

References (24)

1. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9:517-31.
2. Wurzer G, Mosgoeller W, Chabicovsky M, Cerni C, Wesierska-Gadek J. Nuclear Ras: unexpected subcellular distribution of oncogenic forms. J Cell Biochem Suppl. 2001;Suppl 36:1-11.
3. Birchenall-Roberts MC, Fu T, Kim SG, et al. K-Ras4B proteins are expressed in the nucleolus: interaction with nucleolin. Biochem Biophys Res Commun. 2006;348:540-9.
4. Fuentes-Calvo I, Blazquez-Medela AM, Santos E, Lopez-Novoa JM, Martinez-Salgado C. Analysis of k-ras nuclear expression in fibroblasts and mesangial cells. PLoS One. 2010;5:e8703.
5. Elam C, Hesson L, Vos MD, et al. RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res.2005;65:3117-25.
6. Cohen JB, Broz SD, Levinson AD. Expression of the H-ras protooncogene is controlled by alternative splicing. Cell. 1989;58:461-72.
7. Guil S, de La Iglesia N, Fernandez-Larrea J, et al. Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus. Cancer Res.2003;63:5178-87.
8. Jeong MH, Bae J, Kim WH, et al. p19ras interacts with and activates p73 by involving the MDM2 protein. J Biol Chem. 2006;281:8707-15.
9. Kim JW, Kim WH, Jeong MH, et al. p19(ras) amplifies p73betainduced apoptosis through mitochondrial pathway. Biochem Biophys Res Commun. 2008;373:146-50.
10. Hitomi M, Stacey DW. Cellular ras and cyclin D1 are required during different cell cycle periods in cycling NIH 3T3 cells. Mol Cell Biol.1999;19:4623-32.
11. Hitomi M, Stacey DW. Ras-dependent cell cycle commitment during G2 phase. FEBS Lett. 2001;490:123-31.
12. Liu JJ, Chao JR, Jiang MC, Ng SY, Yen JJ, Yang-Yen HF. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol. 1995;15:3654-63.
13. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A. 1998;95:1369-74.
14. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res. 2003;63: 5656-68.
15. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist. 2005;10:565-78.
16. Chang EH, Furth ME, Scolnick EM, Lowy DR. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature.1982;297:479-83.
17. Friedman RM, Yeh A, Gutman P, Contente S, Kenyon K. Reversion by deletion of transforming oncogene following interferon-beta and retinoic acid treatment. J Interferon Cytokine Res. 1997;17:647-51.
18. Samid D, Chang EH, Friedman RM. Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun. 1984;119:21-8.
19. Contente S, Attard FA, Yeh TA, Buchhagen DL, Friedman RM. Deregulated expression of interferon regulatory factor-1 in oncogene- transformed mouse fibroblasts. J Interferon Cytokine Res.2003;23:639-47.
20. Zlatanova JS, Srebreva LN, Banchev TB, Tasheva BT, Tsanev RG. Cytoplasmic pool of histone H1 in mammalian cells. J Cell Sci. 1990; 96(Pt 3):461-8.
21. Hsu LW, Chen CL, Nakano T, et al. The role of a nuclear protein, histone H1, on signalling pathways for the maturation of dendritic cells. Clin Exp Immunol. 2008;152:576-84.
22. Burrows JF, Kelvin AA, McFarlane C, et al. USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. J Biol Chem. 2009;284:9587-95.
23. Singh AK, Sidhu GS, Friedman RM, Maheshwari RK. Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine. J Interferon Cytokine Res.1996;16:725-31.
24. Yeh TJ, Contente S, Friedman RM. Transformation of revertant murine cells by 5-azacytidine results in rapid inhibition of lysyl oxidase expression. Acta Microbiol Immunol Hung.2005;52:433-42.